Immix Biopharma Reports High Complete Response Rate in AL Amyloidosis Trial

Immix Biopharma announced positive Phase 2 clinical trial results for its NEXICART-2 treatment, achieving an 89% complete response rate in 45 patients with relapsed/refractory AL Amyloidosis. An independent review committee assessed the outcomes, noting that all 25 new patients are in complete response or minimum residual disease (MRD)-negative, potentially leading to a 98% complete response rate. No relapses, neurotoxicity, or enterocolitis have been observed, indicating a promising development for this challenging condition.